Gilead Q1 2026 Revenue Beats Estimates, HIV Pipeline Advances
Gilead Sciences (GILD) reported Q1 2026 results with revenue of $6.96 billion and net income of $2.02 billion. The company also announced FDA priority review for its once-daily HIV combination therapy, while large acquisition charges impact full-year adjusted earnings guidance.
Key Numbers
Gilead Sciences (GILD) reported first-quarter 2026 results on early May 2026, with revenue of $6.96 billion and net income of $2.02 billion. The company also advanced its HIV pipeline with FDA priority review for the once-daily bictegravir/lenacapavir combination, while large acquisition-related charges weigh on adjusted earnings guidance.
Key Financial Results
| Metric | Value |
|---|---|
| Revenue | $6.96 billion |
| Net Income | $2.02 billion |
Year-over-year comparisons were not provided.
Highlights from the Report
- FDA granted priority review for once-daily bictegravir/lenacapavir HIV combination.
- Gilead continues share repurchases to return capital to shareholders.
- Significant acquisition charges affect full-year adjusted earnings.
Forward Guidance
Gilead raised its full-year 2026 product sales guidance but expects an adjusted earnings loss per share due to large acquisition-related charges from recent deals.
Stock Impact
No immediate stock price reaction was reported, but investors are monitoring the HIV pipeline progress and the impact of charges on profitability.
What This Means for Investors
The results show strong current product sales, but guidance signals temporary earnings pressure from acquisition charges. The new HIV therapy could drive future growth, though it still requires final FDA approval.
Frequently Asked Questions
Found this useful? Share it